Compounds > 15-keto-13-14-dihydroprostaglandin-f2alpha

15-keto-13-14-dihydroprostaglandin-f2alpha and Neoplasms--Germ-Cell-and-Embryonal

15-keto-13-14-dihydroprostaglandin-f2alpha has been researched along with Neoplasms--Germ-Cell-and-Embryonal* in 1 studies

Other Studies

1 other study(ies) available for 15-keto-13-14-dihydroprostaglandin-f2alpha and Neoplasms--Germ-Cell-and-Embryonal

ArticleYear
13,14-Dihydro-15-keto-prostaglandin F2 alpha in patients with urogenital tumors.
    Urologia internationalis, 1980, Volume: 35, Issue:3

    13,14-Dihydro-15-keto-prostaglandin F2 alpha (13,14-DHK-PGF2 alpha) represents a stable product of degradation after pulmonary flow and it is shown to be reliably measured by radioimmunoassay. In patients with urogenital tumors, serum levels of 13,14-DHK-PGF2 alpha are distinctly elevated when compared to a control group. The rate of synthesis of this compound in urogenital tumors, however, appears to be different.

    Topics: Adenocarcinoma; Dinoprost; Female; Humans; Kidney Neoplasms; Male; Neoplasms, Germ Cell and Embryonal; Prostaglandins F; Prostatic Hyperplasia; Prostatic Neoplasms; Radioimmunoassay; Testicular Neoplasms; Urinary Bladder Neoplasms; Urogenital Neoplasms

1980